https://www.selleckchem.com/products/mitopq.html
07; P=0.51, after last session MD=-0.10; P=0.14), △vascularity(after first session MD=-0.25; P=0.57, after last session MD=-0.02; P=0.79) and △pliability (after last session MD=0.52; P=0.48). Although total adverse effects (RR=0.42; P=0.1) were not significantly different, in the subgroup analysis, the incidence of telangiectasia (RR=0.04; P0.05) and skin atrophy (RR=0.10; P0.05) but not pain (RR=1.27; P=0.77) was significantly lower with verapamil than with TAC. Verapamil may be an effective substitute for TAC. Although total ad
Like
Comment
Share
